Ponatinib dose intensity was shown to be associated with rates of adverse events.
Pancreatitis, rash, and cardiac failure were most strongly associated with dose.
Time-to-event analyses suggest a lag between changes in dose and event risk.
No association between dose intensity and venous thromboembolic events was evident.
Results support investigating approaches to lower average ponatinib dose intensity.